Comments on Bothe, Davidow, Bramlett, Franic, and Ingham (2006).
OBJECTIVE
To critically assess the quality, methodology, and conclusions in A. K. Bothe, J. H. Davidow, R. E. Bramlett, D. M. Franic, and R. J. Ingham's (2006) systematic review of pharmacological approaches to stuttering.


METHODS
A. D. Oxman and G. H. Guyatt's (1988) guidelines for reading literature reviews and A. D. Oxman and G. H. Guyatt's (1991) criteria for assessing the scientific quality of systematic reviews were adopted to accomplish the purpose.


RESULTS
Bothe et al.'s review was rated on a 7-point scale from extensive flaws on the high end to minimal flaws on the low end of the scale. The ratings varied from poor to good.


CONCLUSIONS
We judged Bothe et al.'s review of the pharmacological literature as it pertains to stuttering as flawed in its methodology and conclusions. However, we agree that the existing evidence for the use of pharmacological agents with persons who stutter is insufficient to recommend them in practice. Directions for improving the quality of clinical trials are suggested. In addition, we advocate for the multimethod measurement in stuttering research, including comparison, subjective evaluation, and social impact measures.
Meline
Timothy
T
Harn
William E
WE
D001569:Benzodiazepines / Q000627:therapeutic use; D004358:Drug Therapy / Q000379:methods*; D006801:Humans; D000077152:Olanzapine; D011361:Professional Competence; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013342:Stuttering / Q000188:drug therapy*
D001569:Benzodiazepines; D000077152:Olanzapine; D017367:Selective Serotonin Reuptake Inhibitors